Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Goldenberg

Showing results (31-40 of 318) with videos related to

Pageof 32
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|February 13, 2008
Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electronsM Jules Mattes, David M Goldenberg
Current Opinion in Investigational Drugs (London, England : 2000)|November 28, 2008
Novel radioimmunopharmaceuticals for cancer imaging and therapyRobert M Sharkey, David M Goldenberg
Expert Opinion on Biological Therapy|April 18, 2020
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapyDavid M Goldenberg, Robert M Sharkey
Oncotarget|July 11, 2018
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer targetDavid M Goldenberg, Rhona Stein, Robert M Sharkey
Expert Review of Clinical Immunology|May 19, 2010
Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisalRobert M Sharkey, Jack Burton, David M Goldenberg
Cancer|February 4, 2010
Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclidesRobert M Sharkey, Habibe Karacay, David M Goldenberg
Expert Opinion on Drug Discovery|March 14, 2013
Advances and challenges in developing cytokine fusion proteins as improved therapeuticsChien-Hsing Chang, Pankaj Gupta, David M Goldenberg
Leukemia & Lymphoma|March 11, 2010
Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospectsDavid M Goldenberg, Franck Morschhauser, William A Wegener
Expert Review of Vaccines|April 29, 2009
Novel strategies for improved cancer vaccinesXiaochuan Chen, Chien-Hsing Chang, David M Goldenberg
Bioconjugate Chemistry|December 16, 2011
The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structuresEdmund A Rossi, David M Goldenberg, Chien-Hsing Chang
Pageof 32

Showing results (31-40 of 318) with videos related to

Sort By:
Pageof 32
European Journal of Nuclear Medicine and Molecular Imaging|February 13, 2008
Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electronsM Jules Mattes, David M Goldenberg
Current Opinion in Investigational Drugs (London, England : 2000)|November 28, 2008
Novel radioimmunopharmaceuticals for cancer imaging and therapyRobert M Sharkey, David M Goldenberg
Expert Opinion on Biological Therapy|April 18, 2020
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapyDavid M Goldenberg, Robert M Sharkey
Oncotarget|July 11, 2018
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer targetDavid M Goldenberg, Rhona Stein, Robert M Sharkey
Expert Review of Clinical Immunology|May 19, 2010
Radioimmunotherapy of non-Hodgkin's lymphoma: a critical appraisalRobert M Sharkey, Jack Burton, David M Goldenberg
Cancer|February 4, 2010
Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclidesRobert M Sharkey, Habibe Karacay, David M Goldenberg
Expert Opinion on Drug Discovery|March 14, 2013
Advances and challenges in developing cytokine fusion proteins as improved therapeuticsChien-Hsing Chang, Pankaj Gupta, David M Goldenberg
Leukemia & Lymphoma|March 11, 2010
Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospectsDavid M Goldenberg, Franck Morschhauser, William A Wegener
Expert Review of Vaccines|April 29, 2009
Novel strategies for improved cancer vaccinesXiaochuan Chen, Chien-Hsing Chang, David M Goldenberg
Bioconjugate Chemistry|December 16, 2011
The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structuresEdmund A Rossi, David M Goldenberg, Chien-Hsing Chang
Pageof 32